SCHEMBL4659474

SCHEMBL4659474

O=[N+]([O-])c1ccc2nc(O)cc(O)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TXNRD1 Q16881 1/20 0.49
TXNRD3 Q86VQ6 1/20 0.49
TXNRD2 Q9NNW7 1/20 0.49
OPRK1 P41145 1/20 0.48
KMT2A Q03164 1/20 0.48
ERN1 O75460 1/20 0.47
GPR35 Q9HC97 2/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.46
GAA P10253 1/20 0.46
THRB P10828 1/20 0.46
ACHE P22303 1/20 0.46
GUCY1B2 O75343 1/20 0.46
GUCY1A2 P33402 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5909911 0.84 MEN1 (0.56) ELANEALDH1A1TXNRD1TXNRD3TXNRD2
SCHEMBL6846654 0.84 KMT2A (0.51) ELANEALDH1A1TXNRD1TXNRD3TXNRD2
SCHEMBL17478740 0.84 KMT2A (0.52) ELANEALDH1A1TXNRD1TXNRD3TXNRD2
SCHEMBL2910393 0.83 ALDH1A1 (0.67) ELANEALDH1A1TXNRD1TXNRD3TXNRD2
SCHEMBL6596709 0.80 ALDH1A1 (0.47) ELANEALDH1A1TXNRD1TXNRD3TXNRD2
SCHEMBL29230151 0.80 ELANE (0.45) ELANEALDH1A1TXNRD1TXNRD3TXNRD2
SCHEMBL1257817 0.80 ELANE (0.72) ELANEALDH1A1OPRK1KMT2ASMN1; SMN2
SCHEMBL17478755 0.80 ALDH1A1 (0.71) ELANEALDH1A1KMT2AABCG2
SCHEMBL6201684 0.78 KDM4E (0.50) ELANEALDH1A1KMT2AHPGD
SCHEMBL27258600 0.77 ALDH1A1 (0.53) ELANEALDH1A1KMT2ATP53ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125372-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF ASTELLAS ENG SMALL MOLECULES US INCORPORATED (US) 2026-05-07 US disclosed
EP-4608825-A1 FUSED AZINES AS DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF Astellas Engineered Small Molecules US, Incorporated (US) 2025-09-03 EP disclosed
CN-120077039-A Fusion azines as dynamin-1 like protein inhibitors and uses thereof 安斯泰来工程小分子美国股份有限公司 2025-05-30 CN disclosed
WO-2024091489-A1 FUSED AZINES AS DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF MITOBRIDGE, INC. (US) 2024-05-02 WO disclosed
EP-1819342-A4 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2008-12-17 EP disclosed
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 US disclosed
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 US disclosed
EP-1819342-A1 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-08-22 EP disclosed
WO-2006060390-A1 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-06-08 WO disclosed
US-20050165006-A1 Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same HYUNDAI PHARM. IND. CO., LTD. (KR) 2005-07-28 US disclosed
EP-1373252-A1 CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT Aventis Pharma S.A. (FR) 2004-01-02 EP disclosed
WO-2003082286-A1 QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME CHEMON INC. (KR) 2003-10-09 WO disclosed
WO-2002076975-A1 CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT AVENTIS PHARMA S.A. (FR) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165006-A1 Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same SLC18A2, SLC6A4, SLC6A2 ELANE 4879/4885ALDH1A1 3497/4885TXNRD1 707/4885
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 ELANE 1070/4885ALDH1A1 874/4885TXNRD1 2666/4885
US-20260125372-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF DNM1L, DNM1, DNM2 ELANE 3152/4885ALDH1A1 4578/4885TXNRD1 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.